Illumina (NASDAQ:ILMN) is scheduled to issue its quarterly earnings data after the market closes on Monday, April 23rd. Analysts expect the company to announce earnings of $1.04 per share for the quarter. Illumina has set its FY18 guidance at $4.50-4.60 EPS.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.22. The firm had revenue of $778.00 million during the quarter, compared to analysts’ expectations of $752.04 million. Illumina had a net margin of 26.56% and a return on equity of 21.71%. The business’s quarterly revenue was up 25.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.85 earnings per share. On average, analysts expect Illumina to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Shares of ILMN stock opened at $244.60 on Friday. The company has a quick ratio of 3.55, a current ratio of 3.99 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $36,075.94, a P/E ratio of 61.15, a price-to-earnings-growth ratio of 3.28 and a beta of 0.89. Illumina has a fifty-two week low of $167.98 and a fifty-two week high of $256.64.
In other Illumina news, SVP Oene Mark Van sold 1,400 shares of the business’s stock in a transaction that occurred on Thursday, April 12th. The shares were sold at an average price of $238.48, for a total transaction of $333,872.00. Following the completion of the transaction, the senior vice president now owns 12,217 shares in the company, valued at approximately $2,913,510.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Marc Stapley sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $216.87, for a total transaction of $433,740.00. Following the transaction, the executive vice president now owns 27,952 shares of the company’s stock, valued at approximately $6,061,950.24. The disclosure for this sale can be found here. Insiders have sold a total of 18,008 shares of company stock valued at $4,130,075 in the last quarter. 0.54% of the stock is currently owned by company insiders.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.